DADevika Agarwal

Devika Agarwal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Devika Agarwal has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CD1a-autoreactive T-cell sensing of skin barrier compromise

    by Rosana Ottakandathil Babu, Janina Nahler, Kyla Dooley, Karmella Naidoo, Adrian Kobiela, Soo Weei Ng, John H Ye, Esther Bridges, Devika Agarwal, Alison Simmons, et al.

    Background: T cells are often enriched at barrier tissues, yet little is known about their roles in barrier sensing and relevance to associated disease. CD1a is a major histocompatibility complex class I-like molecule expressed by Langerhans cells, and forms complexes with lipid antigens to facilitate recognition by nonclassical CD1a-reactive T cells. Objectives: To investigate the role of CD1a in the disease pathogenesis of atopic dermatitis (AD). Methods: Human skin challenge, single-cell and spatial transcriptomic-based approaches and functional immunology were used to assess the role of CD1a in AD pathogenesis. Results: Skin allergen challenge in individuals with AD induced skin CCL17 and CCL22 concentrations that promoted CCR4+ T-cell migration. Single-cell resolution proteo-transcriptomics from human lesional AD skin tissue identified a dominant CCL17/CCL22 source as a persistent population of activated skin CD1a+ dendritic cells (DCs) previously shown to be transiently enriched in human skin wounds. Single-cell resolution spatial tissue analyses showed that these cells were predominantly located within lesional subepidermal microcompartment clusters co-localizing with distinct subpopulations of T helper 2 (Th2) cells. Activated skin DCs expressed neutral sphingomyelinase, which processed inhibitory long-chain sphingomyelin to drive Th2 cell CD1a autoreactivity. Conclusions: The findings are consistent with human CD1a-autoreactive T cells sensing chronic skin barrier compromise through the detection of altered sphingomyelin cycle activity, with implications for the pathogenesis of atopic and related disease.


  • Open Access

    ChatMDV: Reducing Technical Barriers in Bioinformatics Analysis using Large Language Models

    by Maria Kiourlappou, Peter Todd, Yaxuan Kong, Jayesh Hire, Sibgathullah Furquan Nawab Mohammed, Devika Agarwal, Martin Sergeant, Stefan Zohren, Brian Marsden, Jim Hughes, et al.

    Background: The rapid advancement in single-cell, spatial omics, imaging, and genomic technologies requires robust analytical and visualisation platforms capable of managing complex biological data. Tools such as Multi-Dimensional Viewer (MDV) offer comprehensive interfaces for data exploration, but often require advanced computational expertise and manual configuration to generate visualisation outputs, limiting accessibility for many users. Results: We present ChatMDV, a natural language interface integrated with MDV that enables users to generate high-quality, interactive visualisations and analyses through natural language commands. ChatMDV employs a retrieval-augmented generation (RAG) pipeline in combination with large language models (LLMs) to translate user queries into executable, reproducible Python code and interactive output. This conversational layer facilitates both exploratory and targeted analyses in diverse biological domains. We demonstrate ChatMDV's capabilities using three datasets of increasing complexity: the Peripheral Blood Mononuclear Cells 3K (PBMC3K) single-cell RNA-sequencing (scRNA-seq) dataset, the lung cancer atlas scRNA-seq dataset included in the Human Cell Atlas and the longitudinal TAURUS study scRNA-seq dataset. Across all use cases, ChatMDV produced high-quality, reproducible visualisations from simple natural language queries, achieving a high semantic success rate between 79% and 97% when visualising the datasets. Conclusions: By bridging the gap between natural language processing and bioinformatics visualisation, ChatMDV reduces technical barriers, enhances reproducibility, and supports more inclusive scientific inquiry. Its modular design and adherence to Findability, Accessibility, Interoperability, and Reuse (FAIR) principles make it a scalable and adaptable framework for accelerating biological data analysis.

  • Open Access

    A High-Resolution Atlas of the Brain Predicts Lineage and Birth Order Underly Neuronal Identity

    by Aaron Munro Allen, Megan C. Neville, Tetsuya Nojima, Faredin Alejevski, Devika Agarwal, David Sims, Stephen F. Goodwin

    SUMMARY: Gene expression shapes the nervous system at every biological level, from molecular and cellular processes defining neuronal identity and function to systems-level wiring and circuit dynamics underlying behaviour. Here, we generate the first high-resolution, single-cell transcriptomic atlas of the adult Drosophila melanogaster central brain by integrating multiple datasets, achieving an unprecedented tenfold coverage of every neuron in this complex tissue. We show that a neuron’s genetic identity overwhelmingly reflects its developmental origin, preserving a genetic address based on both lineage and birth order. We reveal foundational rules linking neurogenesis to transcriptional identity and provide a framework for systematically defining neuronal types. This atlas provides a powerful resource for mapping the cellular substrates of behaviour by integrating annotations of hemilineage, cell types/subtypes and molecular signatures of underlying physiological properties. It lays the groundwork for a long-sought bridge between developmental processes and the functional circuits that give rise to behaviour.


  • SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis

    by Tarek M A Abdel-Fatah, Devika Agarwal, Dong-Xu Liu, Roslin Russell, Oscar M Rueda, Karen Liu, Bing Xu, Paul M Moseley, Andrew R Green, Alan G Pockley, et al.


  • Open Access

    MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours

    by Andrew R Green, Mohammed A Aleskandarany, Devika Agarwal, Somaia Elsheikh, Christopher C Nolan, Maria Diez-Rodriguez, R Douglas Macmillan, Graham R Ball, Carlos Caldas, Srinivasan Madhusudan, et al.

    MYC is amplified in approximately 15% of breast cancers (BCs) and is associated with poor outcome. c-MYC protein is multi-faceted and participates in many aspects of cellular function and is linked with therapeutic response in BCs. We hypothesised that the functional role of c-MYC differs between molecular subtypes of BCs. We therefore investigated the correlation between c-MYC protein expression and other proteins involved in different cellular functions together with clinicopathological parameters, patients’ outcome and treatments in a large early-stage molecularly characterised series of primary invasive BCs (n=1106) using immunuohistochemistry. The METABRIC BC cohort (n=1980) was evaluated for MYC mRNA expression and a systems biology approach utilised to identify genes associated with MYC in the different BC molecular subtypes. High MYC and c-MYC expression was significantly associated with poor prognostic factors, including grade and basal-like BCs. In luminal A tumours, c-MYC was associated with ATM (P=0.005), Cyclin B1 (P=0.002), PIK3CA (P=0.009) and Ki67 (PP=0.003) and p16 (P=0.042) expression only. c-MYC was an independent predictor of a shorter distant metastases-free survival in luminal A LN+ tumours treated with endocrine therapy (ET; P=0.013). In luminal tumours treated with ET, MYC mRNA expression was associated with BC-specific survival (P=0.001). In ER-positive tumours, MYC was associated with expression of translational genes while in ER-negative tumours it was associated with upregulation of glucose metabolism genes. c-MYC function is associated with specific molecular subtypes of BCs and its overexpression confers resistance to ET. The diverse mechanisms of c-MYC function in the different molecular classes of BCs warrants further investigation particularly as potential therapeutic targets.


  • Open Access

    Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer

    by Raghavendra A. Shamanna, Huiming Lu, Deborah L. Croteau, Arvind Arora, Devika Agarwal, Graham Ball, Mohammed A. Aleskandarany, Ian O. Ellis, Yves Pommier, Srinivasan Madhusudan, et al.

    Werner syndrome protein (WRN) is a RecQ helicase that participates in DNA repair, genome stability and cellular senescence. The five human RecQ helicases, RECQL1, Bloom, WRN, RECQL4 and RECQL5 play critical roles in DNA repair and cell survival after treatment with the anticancer drug camptothecin (CPT). CPT derivatives are widely used in cancer chemotherapy to inhibit topoisomerase I and generate DNA double-strand breaks during replication. Here we studied the effects of CPT on the stability and expression dynamics of human RecQ helicases. In the cells treated with CPT, we observed distinct effects on WRN compared to other human RecQ helicases. CPT altered the cellular localization of WRN and induced its degradation by a ubiquitin-mediated proteasome pathway. WRN knockdown cells as well as CPT treated cells became senescent and stained positive for senescence-associated β-galactosidase at a higher frequency compared to control cells. However, the senescent phenotype was attenuated by ectopic expression of WRN suggesting functional implication of WRN degradation in CPT treated cells. Approximately 5-23% of breast cancer tumors are known to respond to CPT-based chemotherapy. Interestingly, we found that the extent of CPT-induced WRN degradation correlates with increasing sensitivity of breast cancer cells to CPT. The abundance of WRN decreased in CPT-treated sensitive cells; however, WRN remained relatively stable in CPT-resistant breast cancer cells. In a large clinical cohort of breast cancer patients, we find that WRN and topoisomerase I expression correlate with an aggressive tumor phenotype and poor prognosis. Our novel observations suggest that WRN abundance along with CPT-induced degradation could be a promising strategy for personalizing CPT-based cancer chemotherapeutic regimens.


  • The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts

    by Mohammed A. Aleskandarany, Devika Agarwal, Ola H. Negm, Graham Ball, Ahmed Elmouna, Ibraheem Ashankyty, Edem Nuglozeh, Mohammad F. Fazaludeen, Maria Diez-Rodriguez, Christopher C. Nolan, et al.

    Signal transducer and activator of transcription (STAT) transcription factors family are involved in diverse cellular biological functions. Reports regarding the prognostic impact of STAT3 expression in breast cancer (BC) are variable whether being a factor of poor or good prognosis. Immunohistochemical expression of phospho-STAT3 (pSTAT3) was studied in large series of invasive BC (n = 1270). pSTAT3 and STAT3 were quantified using reverse phase protein array (RPPA) on proteins extracted from macro-dissected FFPE tissues (n = 49 cases). STAT3 gene expression in the METABRIC cohort was also investigated. STAT3 gene expression prognostic impact was externally validated using the online BC gene expression data (n = 26 datasets, 4.177 patients). pSTAT3 was expressed in the nuclei and cytoplasm of invasive BC cells. Nuclear pSTAT3 overexpression was positively associated with smaller tumour size, lower grade, good NPI, negative lymphovascular invasion (LVI), ER+, PgR+, p53−, HER2−, and low Ki67LI and an improved breast cancer-specific survival (BCSS), independently of other factors. On RPPA, the mean pSTAT3 and STAT3 expressions were higher in ER+, PgR+, and smaller size tumours. Higher STAT3 transcripts in the METABRIC cohort were observed in cases with favourable prognostic criteria and as well as improved BCSS within the whole cohort, ER+ cohort with and without hormonal therapy, and ER− cohort including those who did not receive adjuvant chemotherapy. Pooled STAT3 gene expression data in the external validation cohort showed an association with improved patients’ outcome (P < 0.001, HR = 0.84, 95 % CI 0.79–0.90). Results of this study suggest nuclear localisation of pSTAT3 as favourable prognostic marker in invasive BC, results re-enforced by analysis of STAT3 gene expression data. This good prognostic advantage was maintained in patients who received and who did not receive adjuvant therapy. Therefore, STAT3 could have context-dependent molecular roles of in BC, results which warrant further prospective verification in clinical trials.


  • HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis

    by Tarek M.A. Abdel-Fatah, Stephanie E.B. McArdle, Devika Agarwal, Paul M. Moseley, Andrew R. Green, Graham R. Ball, A. Graham Pockley, Ian O. Ellis, Robert C. Rees, Stephen Y.T. Chan

    Purpose: The expression of HAGE as a novel prognostic and predictive tool was assessed in 1,079 triple-negative breast cancers (TNBC). Experimental Design: HAGE protein expression was investigated in an early primary TNBC (EP-TNBC; n = 520) cohort who received adjuvant chemotherapy (ACT) and in a locally advanced primary TNBC cohort who received anthracycline combination Neo-ACT (n = 110; AC-Neo-ACT). HAGE-mRNA expression was evaluated in the METABRIC-TNBC cohort (n = 311) who received ACT and in a cohort of patients with TNBC who received doxorubicin/cyclophosphamide Neo-ACT, followed by 1:1 randomization to ixabepilone (n = 68) or paclitaxel (n = 64) as part of a phase II clinical trial. Furthermore, a cohort of 128 tumors with integrated HAGE gene copy number changes, mRNA, and protein levels were analyzed. Results: In patients with EP-TNBC, who were chemotherapy-naïve, high HAGE protein expression (HAGE+) was associated with a higher risk of death [HR, 1.3; 95% confidence interval (CI), 1.2–1.5; P = 0.000005] when compared with HAGE− cases. Patients who received ACT and expressed mRNA-HAGE+ were at a lower risk of death than those who were mRNA–HAGE− (P = 0.004). The expression of HAGE was linked to the presence of tumor-infiltrating lymphocytes (TIL), and both features were found to be independent predictors for pathologic complete response (pCR, P < 0.001) and associated with prolonged survival (P < 0.01), following AC-Neo-ACT. In patients with residual disease, HAGE+ had a 2-fold death risk increase (P = 0.018) compared with HAGE−. Conclusions: HAGE expression is a potential prognostic marker and a predictor of response to anthracycline treatment in TNBC. A prospective clinical trial to examine the therapeutic value of HAGE for TNBC cases is warranted. Clin Cancer Res; 22(4); 905–14. ©2015 AACR.


  • Open Access

    RECQL4 helicase has oncogenic potential in sporadic breast cancers

    by Arvind Arora, Devika Agarwal, Tarek Ma Abdel‐Fatah, Huiming Lu, Deborah L Croteau, Paul Moseley, Mohammed A Aleskandarany, Andrew R Green, Graham Ball, Emad A Rakha, et al.

    RECQL4 helicase is a molecular motor that unwinds DNA, a process essential during DNA replication and DNA repair. Germ‐line mutations in RECQL4 cause type II Rothmund–Thomson syndrome (RTS), characterized by a premature ageing phenotype and cancer predisposition. RECQL4 is widely considered to be a tumour suppressor, although its role in human breast cancer is largely unknown. As the RECQL4 gene is localized to chromosome 8q24, a site frequently amplified in sporadic breast cancers, we hypothesized that it may play an oncogenic role in breast tumourigenesis. To address this, we analysed large cohorts for gene copy number changes (n = 1977), mRNA expression (n = 1977) and protein level (n = 1902). Breast cancer incidence was also explored in 58 patients with type II RTS. DNA replication dynamics and chemosensitivity was evaluated in RECQL4‐depleted breast cancer cells in vitro. Amplification or gain in gene copy number (30.6%), high‐level mRNA expression (51%) and high levels of protein (23%) significantly associated with aggressive tumour behaviour, including lymph node positivity, larger tumour size, HER2 overexpression, ER‐negativity, triple‐negative phenotypes and poor survival. RECQL4 depletion impaired the DNA replication rate and increased chemosensitivity in cultured breast cancer cells. Thus, although recognized as a 'safe guardian of the genome', our data provide compelling evidence that RECQL4 is tumour promoting in established breast cancers. Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


  • Open Access

    Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers

    by Arvind Arora, Tarek M.A. Abdel-Fatah, Devika Agarwal, Rachel Doherty, Deborah L. Croteau, Paul M. Moseley, Khalid Hameed, Andrew Green, Mohammed A. Aleskandarany, Emad A. Rakha, et al.

    RECQL5 is a member of the RecQ family of DNA helicases and has key roles in homologous recombination, base excision repair, replication and transcription. The clinicopathological significance of RECQL5 expression in breast cancer is unknown. In this study, we have evaluated RECQL5 mRNA expression in 1977 breast cancers, and RECQL5 protein level in 1902 breast cancers [Nottingham Tenovus series ( n = 1650) and ER− cohort ( n = 252)]. Expression levels were correlated to aggressive phenotypes and survival outcomes. High RECQL5 mRNA expression was significantly associated with high histological grade ( P = 0.007), HER2 overexpression ( P = 0.032), ER+/HER2−/high proliferation genefu subtype ( P < 0.0001), integrative molecular clusters (intClust 1and 9) ( P < 0.0001) and poor survival ( P < 0.0001). In subgroup analysis, high RECQL5 mRNA level remains significantly associated with poor BCSS in ER+ cohort ( P < 0.0001) but not in ER− cohort ( P = 0.116). At the protein level, in tumours with low RAD51, high RECQL5 level was significantly associated with high histological grade ( P < 0.0001), higher mitotic index ( P = 0.008), dedifferentiation ( P = 0.025), pleomorphism ( P = 0.027) and poor survival ( P = 0.003). In subgroup analysis, high RECQL5/low RAD51 remains significantly associated with poor BCSS in ER+ cohort ( P = 0.010), but not in ER− cohort ( P = 0.628). In multivariate analysis, high RECQL5 mRNA and high RECQL5/low RAD51 nuclear protein coexpression independently influenced survival ( P = 0.022) in whole cohort and in the ER+ subgroup. Preclinically, we show that exogenous expression of RECQL5 in MCF10A cells can drive proliferation supporting an oncogenic function for RECQL5 in breast cancer. We conclude that RECQL5 is a promising biomarker in breast cancer.